FRANKFURT (Reuters) - German healthcare conglomerate Fresenius SE & Co posted a 20 percent gain in first-half net income as its injectable generic drugs unit Kabi benefits from rivals' supply shortages. Fresenius, which failed to take over Rhoen-Klinikum, said adjusted net income in the first six months rose to 434 million euros ($534 million), broadly in line with the average estimate of 429 million in a Reuters poll among analysts. ... Continue reading...
No comments:
Post a Comment